SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Trial details
- Registry ID
- NCT06239480
- Drugs studied
- QTORIN 3.9% Rapamycin Anhydrous Gel
TrialRedline tracks 8 clinical trials sponsored by Palvella Therapeutics, Inc.: 3 Phase 3, 1 Phase 2 / 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic MalformationsNCT06239480 | QTORIN 3.9% Rapamycin Anhydrous Gel | Active not recruiting | 2026-01-14Actual |
| A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia CongenitaNCT05180708 | QTORIN 3.9% rapamycin anhydrous gel, Vehicle | Completed | 2023-06-30Actual |
| VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia CongenitaNCT04520750 | PTX-022 | Completed | 2021-06-30Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia CongenitaNCT03920228 | PTX-022 | Completed | 2020-09-19Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)NCT07552077 | PTX-022 | Recruiting | 2027-08Estimated |
| A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous MalformationsNCT06653842 | QTORIN 3.9% rapamycin anhydrous gel | Active not recruiting | 2025-11-21Actual |
| CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin SyndromeNCT04893486 | PTX-022, Vehicle comparator | Completed | 2023-03-13Actual |
| Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic MalformationsNCT05050149 | PTX-022 | Completed | 2022-11-15Actual |
Names as written in the registry records.
NCT06653842 · Palvella Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: Dec 2025. After: 21 Nov 2025.
Before: Recruiting. After: Active not recruiting.
NCT06239480 · Palvella Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: 40 participants (planned). After: 51 participants (actual).
Before: Estimated. After: Actual.
Before: Jan 2026. After: 14 Jan 2026.
Before: Recruiting. After: Active not recruiting.